PBAC's latest decision on Saxagliptin and metformin extended release: Recommended (2015). Considered for Extension of PBS indication for saxagliptin+metformin XR to include use in combination with a sulfonylurea (triple oral therapy) for the treatment of type 2 diabetes mellitus.
PBAC outcome
Recommended
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2015
Submissions
1
2015 → 2015
Eligible population
Adults with type 2 diabetes mellitus with HbA1c greater than 7% prior to initiation of a DPP4 inhibitor, thiazolidinedione, glucagon-like peptide-1, or SGLT2 inhibitor despite treatment with maximally tolerated doses of metformin and a sulfonylurea, or with alternative blood glucose monitoring criteria where HbA1c is clinically inappropriate.
Therapy area
Endocrinology
Line of therapy
Later-line
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
saxagliptin and metformin administered as separate components; sitagliptin+metformin FDC
Economic model
Cost-minimisation
ICER note
This was a minor submission based on cost-minimisation analysis using bioequivalence data from previous submissions. No new ICER was calculated.